Phase 3 Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a laboratory-confirmed diagnosis of one of three types of cervical cancer: squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma
- People whose cervical cancer has persisted, come back after treatment, or has been newly diagnosed as having spread to distant parts of the body (advanced stage), and where surgery or radiation cannot cure it
- People living with HIV, provided their HIV is well controlled with medication
- People who have hepatitis B, provided they are on antiviral treatment and the virus is undetectable in their blood
- People with a history of hepatitis C, provided the virus is undetectable in their blood
- People whose general health and ability to carry out daily activities meets a specific standard (rated 0 or 1 on a medical scale, meaning fully active or able to carry out light activity) (confirm with trial site)
- People whose tumor tests positive for a protein called PD-L1 at a certain level (combined positive score of 1 or higher) (confirm with trial site)
Who may not be able to join:
- People living with HIV who have a history of a cancer called Kaposi's sarcoma or a condition called Multicentric Castleman's Disease
- People with a history of serious dry eye syndrome, serious eyelid gland disease, serious eyelid inflammation, or serious corneal conditions that affect healing
- People with active inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) requiring immune-suppressing medication, or who have a history of these conditions or long-term diarrhoea
- People with serious, uncontrolled heart or blood vessel disease, or serious brain and blood vessel disease
- People who have previously received certain types of cancer treatment that fall outside what this trial allows (confirm with trial site)
- People currently taking certain strong medications that affect how the body processes drugs, if those medications cannot be stopped during the trial (confirm with trial site)
- People who have been diagnosed with an immune system deficiency condition
- People who have another cancer that is still growing or has required active treatment within the past three years
- People with active cancer that has spread to the brain or the lining around the brain and spinal cord
- People with an active autoimmune disease that has needed medical treatment in the past two years (note: hormone or natural replacement therapies such as thyroid medication, insulin, or low-dose steroids may still be acceptable)
- People with a history of non-infectious lung inflammation that needed steroid treatment, or who currently have or are suspected to have lung inflammation that cannot be ruled out
- People who have previously had a stem cell or solid organ transplant
- People who have not fully recovered from major surgery, or who are still experiencing complications from surgery
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Merck Sharp & Dohme LLC
Phone: 1-888-577-8839
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1 Safety Run-in: Number of Participants Who Experience One or More Adverse Events (AEs); Part 1 Safety Run-in: Number of Participants Who Discontinue Study Treatment Due to an AE; Part 2 Maintenance Treatment: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR); Part 2 Maintenance Treatment: Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.